|Other names||LY-272,015; 1-[(3,4-Dimethoxyphenyl)methy]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||336.426 g/mol g·mol−1|
|3D model (JSmol)|
LY-272,015 is a beta-carboline derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT2B receptor. It has anti-hypertensive effects in animal models, and is also used in research into the other functions of the 5-HT2B receptor.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|